Washington State University

84 total trials 74 currently recruiting 7 completed

Trial Pipeline

RECRUITING Phase 2

Effects of Hemp-Derived Cannabinoids on Menopause Symptoms

NCT07393672

RECRUITING

Developing a Music Listening mHealth Intervention for Stress Reduction in Early Recovery

NCT07052318

RECRUITING Phase 2

Impact of Cannabinoids on Menopause Symptoms

NCT06831916

RECRUITING NA

FAmily Engagement Strategy for Coordinated Specialty Care

NCT06945055

RECRUITING NA

Cognition After OSA Treatment Among Native American People (CATNAP)

NCT06227572

RECRUITING NA

Acute Psychological and Physiological Effects of Cannabigerol

NCT06638996

RECRUITING Early Phase 1

Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach

NCT06693960

RECRUITING Early Phase 1

Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

NCT06692933

RECRUITING NA

Virtual Incentive Treatment for Alcohol

NCT06265506

RECRUITING Phase 2

Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment

NCT06323837

RECRUITING NA

Automated Reinforcement Management Systems, Phase II

NCT06456905

RECRUITING Early Phase 1

Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac

NCT06053411

RECRUITING Early Phase 1

Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints

NCT05846451

RECRUITING NA

Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation

NCT05733442

RECRUITING NA

Family Peer Navigator for Early Psychosis for Black Families

NCT05284721

RECRUITING NA

Indian Transforming Alzheimer's Care Training (INTACT)

NCT06397339

RECRUITING Phase 2

Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking

NCT05181891

RECRUITING Phase 2

The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study

NCT05134857

ACTIVE NOT RECRUITING NA

Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women

NCT04783558

ACTIVE NOT RECRUITING Phase 1

Hyperbaric Oxygen Treatment (HBOT) During Methadone Tapering

NCT05924022

ACTIVE NOT RECRUITING NA

Caring Contacts: A Strength-based, Suicide Prevention Trial in 4 Native Communities

NCT02825771

COMPLETED NA

Community-Engaged Options to Facilitate Opioid Reduction

NCT05098158

COMPLETED NA

Naturalistic Monitoring and Treatment of Chronic Insomnia

NCT04013321

COMPLETED NA

Phosphatidylethanol-Based Contingency Management for Housing

NCT04038021

COMPLETED NA

Barley Beta-glucan, Glycemic Control, and Appetite

NCT06146322

COMPLETED NA

Motivational Incentives for Alcohol Abstinence in American Indian and Native Alaskan Adults

NCT02174315

COMPLETED NA

Regional Native American Community Networks Program (RNACNP)

NCT02843217

COMPLETED Phase 1

Vitamin C Supplementation as a Preventive Treatment of Diabetic Peripheral Neuropathy

NCT00634998

What the Pipeline for Washington State University Shows

According to the ClinicalTrials.gov registry, Washington State University is linked to 84 US clinical trials across every stage of research activity. Of those, 74 studies are currently recruiting — about 88% of the sponsor's indexed portfolio — and 7 are already marked complete, representing roughly 8% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Washington State University reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 39 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Washington State University is Alcohol Use Disorder (AUD) with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial